United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 7 minute read Healthcare Industry News Inside Galderma’s blockbuster Q3: Why EQT cashed out CHF690m amid record dermatology growth Find out why EQT exited CHF 690 million in Galderma shares as the dermatology major raised full-year growth guidance after strong Q3 results. bySrinathOctober 31, 2025